Muvalaplin, a drug targeting lipoprotein (a), has successfully passed phase II clinical trials, demonstrating reductions of up to 85.7% in lipoprotein (a) levels over twelve weeks with a favorable safety profile comparable to placebo.
A new clinical study shows that Pain Coping Skills Training (PCST), a cognitive behavioural therapy-based approach, significantly reduced pain interference in daily activities for dialysis patients, offering a promising non-drug alternative to traditional pain management.
An analysis of key performance indicators for payor enrollment success, offering data-driven metrics, practical tracking strategies, and actionable tips to help healthcare organizations reduce delays and improve enrollment efficiency.